12S127: Difficult to Treat Rheumatoid Arthritis (DTTRA)

Saturday, November 12, 2022

3:00 PM – 4:00 PM Eastern Time

Location: Terrace Ballroom II&III

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Moderator(s)

ED

Eric Dein, MD, RhMSUS

Institute of Rheumatic and Autoimmune Diseases, Overlook Hospital
Jersey City, NJ, United States

Disclosure(s): No financial relationships to disclose
Daniel Solomon, MD, MPH

Brigham and Women's Hospital
Newton, MA, United States

Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); CorEvitas: Grant/Research Support (Ongoing); moderna: Grant/Research Support (Ongoing)

This session will address clinical practice, basic science, and the future research agenda of difficult to treat rheumatoid arthritis (RA). Speakers will provide basic science insight into potential mechanisms in the inflammatory tissue microenvironment. Learners will gain knowledge regarding the future research agenda for further investigation in refractory RA.

Learning Objectives:

Define difficult to treat rheumatoid arthritis (RA)
Describe key biologic and clinical characteristics of difficult to treat RA
Outline the future directions of treatment and research in difficult to treat RA

Presentations:

3:00 PM – 3:15 PM Eastern Time

Clinical Overview: Difficult to Treat RA
Speaker: Iris Navarro-Millán, MD – Weill Cornell Medicine, Hospital for Special Surgery
3:15 PM – 3:20 PM Eastern Time

Q&A
3:20 PM – 3:35 PM Eastern Time

Synovial Tissue Microenvironment: Insight into New Therapies
Speaker: Christopher Buckley, MD, PhD – University of Oxford
3:35 PM – 3:40 PM Eastern Time

Q&A
3:40 PM – 3:55 PM Eastern Time

Research Agenda into DTTRA
Speaker: S. Louis Bridges, Jr, MD, PhD – Hospital for Special Surgery
3:55 PM – 4:00 PM Eastern Time

Q&A